雙傑電氣(300444.SZ):簽訂共計15.55億元合同
格隆匯3月25日丨雙傑電氣(300444.SZ)公佈,公司和全資子公司雙傑新能有限公司(簡稱“雙傑新能”)於近日與中國電建集團北京勘測設計研究院有限公司分別簽訂《寧夏電投永利能源有限公司股權投資+寧夏電投永利(中衛)新能源有限公司300萬千瓦光伏基地項目EPC總承包35kV箱式變電站及其附屬設備採購項目採購合同》及《寧夏電投永利(中衛)新能源有限公司300萬千瓦光伏基地項目EPC總承包項目3標段工程合同》,合同總金額分別爲人民幣56,694,928元和1,498,557,082.31元,共計人民幣1,555,252,010.31元,除稅後約佔公司2023年經審計營業收入的44.35%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.